New Developments in Inflammatory Skin Diseases

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 5296

Special Issue Editor

Infection Immunology, Leibniz Institute for Natural Product Research and Infection Biology, 07743 Jena, Germany
Interests: T cells; tissue resident memory T cells (TRM); skin immunology; Th17 cells; IL-10
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The skin is a large niche for a highly specialized immune system. It provides first-line barrier protection from pathogens and also orchestrates tolerance to a diverse community of commensal microbes. Dysregulation of the cutaneous immune system results in many chronic inflammatory skin diseases, such as psoriasis or atopic dermatitis. Specific T cell subsets have been attributed roles in the pathogenesis of chronic inflammatory diseases. Th17 cells, for example, play important roles in the pathogenesis of psoriasis as supported by the high clinical success of IL-17 blocking antibodies. Th2 cells, on the other hand, are important in atopic dermatitis. Accordingly, IL-14 and IL-13 blocking drugs have shown high clinical efficacy. Further, Treg dysregulation and roles for other T cell subsets and their functional states have been reported to be relevant for these and other skin diseases. The reasons and mechanisms for T cell dysregulation in the human skin are poorly understood. An aberrant host-microbiota crosstalk has recently emerged as a potential cause for skin diseases. Other factors from the skin microenvironment such as ions, metabolites, and hormones also have an impact on skin immunity. In this Special Issue, new developments in the pathogenesis of inflammatory diseases and their response to new treatments and immunomodulation will be gathered.

Prof. Dr. Christina Zielinski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin inflammation
  • cytokines
  • psoriasis
  • atopic dermatitis
  • biologicals

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

13 pages, 3297 KiB  
Article
Topical Administration of Gardenia jasminoides Extract Regulates Th2 Immunity in OVA-Induced Mice
by Sun Haeng Park, Hyun-Kyung Song, Kon-Young Ji, Dong Ho Jung, Seol Jang, Taesoo Kim and Ho Kyoung Kim
Cells 2023, 12(6), 941; https://doi.org/10.3390/cells12060941 - 20 Mar 2023
Viewed by 1347
Abstract
A key feature of an allergic immune response is a T helper type 2 (Th2)-mediated response with production of allergen-specific IgE antibodies. Gardenia jasminoides extract with the crocin removed (GJExCR) has been shown to inhibit IgE-mediated allergic disease. To evaluate the efficacy and [...] Read more.
A key feature of an allergic immune response is a T helper type 2 (Th2)-mediated response with production of allergen-specific IgE antibodies. Gardenia jasminoides extract with the crocin removed (GJExCR) has been shown to inhibit IgE-mediated allergic disease. To evaluate the efficacy and mechanism-of-action of this inhibition, GJExCR was used in an ovalbumin (OVA)-induced allergy model in BALB/C mice. Sensitization of BALB/C mice with OVA and aluminum hydroxide was performed on days 1 and 14 by intraperitoneal injection, followed by OVA challenge to the dorsal skin for 2 weeks before removal. Seven days post-challenge, mice were treated with GJExCR topically every day for 11 days. Enzyme-linked immunosorbent assay, flow cytometry analysis, real-time PCR, and western blot were performed to determine IgE and Th2 cytokine levels. Following OVA challenge, Th2 cytokine expression and both total and OVA-specific serum IgE levels increased, of which OVA-specific IgE and Th2 cytokine levels decreased after GJExCR treatment. Flow cytometry analysis revealed that GJExCR treatment decreased CD4+ and CD8+ T cell populations in the spleen and lymph nodes. In addition, treatment with GJExCR downregulated signal transducer and activator of transcription 1 (STAT1) activation and Th2 cytokine levels as compared to control. GJExCR containing geniposide downregulated STAT1 activation in HaCaT cells. These findings demonstrate that GJExCR exerts its anti-allergy effect via inhibition of STAT1 activation, thus regulating the immune response via modulation of Th2 cytokine release and IgE levels. Therefore, we propose GJExCR as a potential treatment for allergic hypersensitivity reactions. Full article
(This article belongs to the Special Issue New Developments in Inflammatory Skin Diseases)
Show Figures

Figure 1

13 pages, 538 KiB  
Article
Evidence for Epistatic Interaction between HLA-G and LILRB1 in the Pathogenesis of Nonsegmental Vitiligo
by Maria Luiza de Oliveira-Caramez, Luciana Veiga-Castelli, Andreia S. Souza, Renata Nahas Cardili, David Courtin, Milena Flória-Santos, Eduardo Donadi, Silvana Giuliatti, Audrey Sabbagh, Erick C. Castelli and Celso Teixeira Mendes-Junior
Cells 2023, 12(4), 630; https://doi.org/10.3390/cells12040630 - 15 Feb 2023
Cited by 1 | Viewed by 1412
Abstract
Vitiligo is the most frequent cause of depigmentation worldwide. Genetic association studies have discovered about 50 loci associated with disease, many with immunological functions. Among them is HLA-G, which modulates immunity by interacting with specific inhibitory receptors, mainly LILRB1 and LILRB2. Here we [...] Read more.
Vitiligo is the most frequent cause of depigmentation worldwide. Genetic association studies have discovered about 50 loci associated with disease, many with immunological functions. Among them is HLA-G, which modulates immunity by interacting with specific inhibitory receptors, mainly LILRB1 and LILRB2. Here we investigated the LILRB1 and LILRB2 association with vitiligo risk and evaluated the possible role of interactions between HLA-G and its receptors in this pathogenesis. We tested the association of the polymorphisms of HLA-G, LILRB1, and LILRB2 with vitiligo using logistic regression along with adjustment by ancestry. Further, methods based on the multifactor dimensionality reduction (MDR) approach (MDR v.3.0.2, GMDR v.0.9, and MB-MDR) were used to detect potential epistatic interactions between polymorphisms from the three genes. An interaction involving rs9380142 and rs2114511 polymorphisms was identified by all methods used. The polymorphism rs9380142 is an HLA-G 3′UTR variant (+3187) with a well-established role in mRNA stability. The polymorphism rs2114511 is located in the exonic region of LILRB1. Although no association involving this SNP has been reported, ChIP-Seq experiments have identified this position as an EBF1 binding site. These results highlight the role of an epistatic interaction between HLA-G and LILRB1 in vitiligo pathogenesis. Full article
(This article belongs to the Special Issue New Developments in Inflammatory Skin Diseases)
Show Figures

Figure 1

Other

Jump to: Research

19 pages, 1692 KiB  
Systematic Review
Using a Topical Formulation of Vitamin D for the Treatment of Vitiligo: A Systematic Review
by Khadeejeh Al-Smadi, Masood Ali, Seyed Ebrahim Alavi, Xuping Jin, Mohammad Imran, Vania R. Leite-Silva and Yousuf Mohammed
Cells 2023, 12(19), 2387; https://doi.org/10.3390/cells12192387 - 30 Sep 2023
Cited by 2 | Viewed by 2125
Abstract
Vitamin D is one significant prohormone substance in human organ systems. It is a steroidal hormone produced in the skin upon exposure to UVB rays. This paper presents a systematic review of the utilization of topical vitamin D, specifically cholecalciferol, calcipotriol, and tacalcitol, [...] Read more.
Vitamin D is one significant prohormone substance in human organ systems. It is a steroidal hormone produced in the skin upon exposure to UVB rays. This paper presents a systematic review of the utilization of topical vitamin D, specifically cholecalciferol, calcipotriol, and tacalcitol, in the treatment of vitiligo. It considers the role of vitamin D in stimulating the synthesis of melanin and melanogenesis, which can help with the process of repigmentation. The inclusion of calcipotriol or tacalcitol in Narrowband Ultraviolet Phototherapy (NB-UVB) has shown the potential to enhance therapeutic outcomes for vitiligo. However, their effectiveness in combination with Psoralens Long Wave Ultraviolet Radiation (PUVA) and Monochromatic Excimer Light (MEL) treatment for vitiligo is limited. In contrast, combining topical corticosteroids with vitamin D analogues has demonstrated superior efficacy in treating vitiligo compared to using vitamin D analogues alone, while also providing the added benefit of reducing corticosteroid-related adverse effects. In addition, treating stable vitiligo with topical cholecalciferol and microneedling has shown success. Future studies are needed to ascertain an efficient method of administering vitamin D topically as an anti-vitiligo agent. Full article
(This article belongs to the Special Issue New Developments in Inflammatory Skin Diseases)
Show Figures

Graphical abstract

Back to TopTop